Custom Search
Doxepin News
Somaxon Pharmaceuticals Announces Presentation Of Phase 2 SILENOR(TM) Data At The Associated Professional Sleep Societies Annual Meeting
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced that data from its Phase 2 clinical trial evaluating three doses of SILENOR(TM) (doxepin HCL) in elderly adults with insomnia will be presented at the SLEEP 2006 Annual...
Somaxon Pharmaceuticals Announces Positive Phase 3 Results with SILENOR™ for the Treatment of Adults with Chronic Insomnia
SILENOR™ demonstrated statistically significant improvements in the primary endpoint: Wake After Sleep Onset.
Displaying results 6 to 7 out of 7